Ισραήλ - Εβραϊκά - Ministry of Health

abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 30 mg - octreotide

Ισραήλ - Εβραϊκά - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Ισραήλ - Εβραϊκά - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Ισραήλ - Εβραϊκά - Ministry of Health

eldan electronic instruments co ltd - ioflupane - תמיסה להזרקה - ioflupane 74 mbq/ml - iodine ioflupane (123i) - other dopaminergic agents - datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum: - of patients with clinically uncertain parkinsonian syndromes in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson's disease multiple system atrophy and progressive supranuclear palsy. - datscan is unable to discriminate between parkinson's disease multiple system atrophy and progressive supranuclear palsy. - to help differentiate probable dementia with lewy bodies from alzheimer's disease. datscan is unable to discriminate between dementia with lewy bodies and parkinson's disease dementia

Ισραήλ - Εβραϊκά - Ministry of Health

taro international ltd, israel - ezetimibe - טבליה - ezetimibe 10 mg - ezetimibe

Ισραήλ - Εβραϊκά - Ministry of Health

pfizer pharmaceuticals israel ltd - dinoprost trometamol 5 mg / 1 ml - solution for injection - dinoprost - therapeutic termination of pregnancy second trimester by intra-amniotic administration.

Ισραήλ - Εβραϊκά - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dinoprostone - תמיסה להזרקה - dinoprostone 10 mg/ml - dinoprostone - dinoprostone - therapeutic termination of pregnancy, missed abortion.

Ισραήλ - Εβραϊκά - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 150 mg/ml - medroxyprogesterone - medroxyprogesterone - for contraception where medically indicated and oral administration is inapplicable.

Ισραήλ - Εβραϊκά - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

Ισραήλ - Εβραϊκά - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.